Guselkumab Plus Golimumab Promising Combination For Ulcerative Colitis Patients who received combination therapy with guselkumab and golimumab followed by maintenance treatment with guselkumab achieved clinical remission a (mmayo b) at week 38 (47.9 percent [34 71]) versus 31.0 percent (22 71) and 20.8 percent (15 72) of patients who received guselkumab or golimumab alone, respectively (nominal p=<0.05). 1. At week 38, 34 (48%) of 71 patients in the combination therapy group, 15 (21%) of 72 patients in the golimumab monotherapy group, and 22 (31%) of 71 patients in the guselkumab group had clinical remission according to the modified mayo score and 49 (69%) patients in the combination therapy group, 43 (60%) patients in the golimumab monotherapy.
Guselkumab Golimumab Combination Therapy Achieves Clinical Remission Data from an ongoing analysis of a phase 2a trial showed that adults with moderately to severely active ulcerative colitis (uc) administered 12 weeks of combination induction therapy with guselkumab (janssen pharmaceutical companies of johnson & johnson) and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate at week 39 of 47.9%. At week 12, 59 (83%) of 71 patients in the combination therapy group had achieved clinical response compared with 44 (61%) of 72 patients in the golimumab monotherapy group (adjusted treatment difference 22·1% [80% ci 12·9 to 31·3]; nominal p=0·0032) and 53 (75%) of 71 patients in the guselkumab monotherapy group (adjusted treatment. Patients were randomly assigned (1:1:1) to combination . guselkumab plus golimumab induction therapy, followed by guselkumab maintenance monotherapy (hereafter referred to as combination therapy), guselkumab monotherapy, or golimumab mono therapy. patients were randomly assigned using an interactive web response system generated by an. Clinical response: a a greater proportion of patients who received combination therapy of guselkumab and golimumab achieved the primary endpoint of clinical response a at week 12 (83.1 percent [59.
Guselkumab Golimumab Combination Provides Superior Clinical Remission Patients were randomly assigned (1:1:1) to combination . guselkumab plus golimumab induction therapy, followed by guselkumab maintenance monotherapy (hereafter referred to as combination therapy), guselkumab monotherapy, or golimumab mono therapy. patients were randomly assigned using an interactive web response system generated by an. Clinical response: a a greater proportion of patients who received combination therapy of guselkumab and golimumab achieved the primary endpoint of clinical response a at week 12 (83.1 percent [59. Adults with moderately to severely active ulcerative colitis (uc) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate of 47.9% at week 38, according to data from an ongoing analysis of a phase 2a clinical trial . At week 12, 59 (83%) of 71 patients in the combination therapy group had achieved clinical response compared with 44 (61%) of 72 patients in the golimumab monotherapy group (adjusted treatment difference 22·1% [80% ci 12·9 to 31·3]; nominal p=0·0032) and 53 (75%) of 71 patients in the guselkumab monotherapy group (adjusted treatment.
Efficacy And Safety Of Combination Induction Therapy With Guselkumab Adults with moderately to severely active ulcerative colitis (uc) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate of 47.9% at week 38, according to data from an ongoing analysis of a phase 2a clinical trial . At week 12, 59 (83%) of 71 patients in the combination therapy group had achieved clinical response compared with 44 (61%) of 72 patients in the golimumab monotherapy group (adjusted treatment difference 22·1% [80% ci 12·9 to 31·3]; nominal p=0·0032) and 53 (75%) of 71 patients in the guselkumab monotherapy group (adjusted treatment.
Guselkumab Golimumab Combo Shows Promise For Ulcerative Colitis
Comments are closed.